Prognostic markers in early-stage colorectal cancer: Significance of TYMS mRNA expression

Anticancer Research

Volumn 34, Issue 9, 2014, Pages 4949-4962

  Koumarianou, Anna ^a   Tzeveleki, Ioanna ^b   Mekras, Dimosthenis ^b   Eleftheraki, Anastasia G ^c   Bobos, Mattheos ^b   Wirtz, Ralph ^d   Fountzilas, Elena ^b   Valavanis, Christos ^e   Xanthakis, Ioannis ^b   Kalogeras, Konstantine T ^b,c   Basdanis, George ^b   Pentheroudakis, George ^f   Kotoula, Vassiliki ^b   Fountzilas, George ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Hellenic Cooperative Oncology Group   (Greece)

^d STRATIFYER Molecular Pathology GmbH   (Germany)

^e METAXA CANCER HOSPITAL   (Greece)

^f UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

5 FU based adjuvant chemotherapy; COX2; DPYD; Hierarchical clustering; PTGS2; Stage II colorectal cancer; Stage III colorectal cancer; TOPO1; TYMP; TYMS

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; CYCLOOXYGENASE 2; DIHYDROPYRIMIDINE DEHYDROGENASE; DIOXYGENASE; DNA TOPOISOMERASE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MESSENGER RNA; OXALIPLATIN; PEROXIDASE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE 2; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; EARLY CANCER; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; VERY ELDERLY; 5-FU-BASED ADJUVANT CHEMOTHERAPY; CANCER GRADING; CLUSTER ANALYSIS; COLORECTAL TUMOR; COX2; DPYD; GENE EXPRESSION REGULATION; GENETICS; HIERARCHICAL CLUSTERING; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PTGS2; STAGE II COLORECTAL CANCER; STAGE III COLORECTAL CANCER; TOPO1; TREATMENT OUTCOME; TYMP; TYMS;

5-FU-BASED ADJUVANT CHEMOTHERAPY; COX2; DPYD; HIERARCHICAL CLUSTERING; PTGS2; STAGE II COLORECTAL CANCER; STAGE III COLORECTAL CANCER; TOPO1; TYMP; TYMS;

ADULT; AGED; AGED, 80 AND OVER; CLUSTER ANALYSIS; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84908688768     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Bray F, Ren JS, Masuyer E and Ferlay J: Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 132: 1133-1145, 2013.
2. Jemal A, Siegel R, Xu J, and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
3. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F and de Gramont A: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27: 3109-3116, 2009.
4. Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP and Goldberg RM: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22: 1797-1806, 2004.
5. Figueredo A, Coombes ME and Mukherjee S: Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev: CD005390, 2008.
6. Williams CS and DuBois RN: Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 270: G393-400, 1996.
7. Wang D and Dubois RN: Eicosanoids and cancer. Nat Rev Cancer 10: 181-193, 2010.
8. Kettunen HL, Kettunen AS and Rautonen NE: Intestinal immune responses in wild-type and Apcmin/+ mouse, a model for colon cancer. Cancer Res 63: 5136-5142, 2003.
9. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ and Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60: 1306-1311, 2000.
10. Yang VW, Shields JM, Hamilton SR, Spannhake EW, Hubbard WC, Hylind LM, Robinson CR and Giardiello FM: Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res 58: 1750-1753, 1998.
11. Nazki FH, Sameer AS and Ganaie BA: Folate: metabolism, genes, polymorphisms and the associated diseases. Gene 533: 11-20, 2014.
12. Wang TL, Diaz LA Jr., Romans K, Bardelli A, Saha S, Galizia G, Choti M, Donehower R, Parmigiani G, Shih Ie M, Iacobuzio-Donahue C, Kinzler KW, Vogelstein B, Lengauer C and Velculescu VE: Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA 101: 3089-3094, 2004.
13. Miyadera K, Sumizawa T, Haraguchi M, Yoshida H, Konstanty W, Yamada Y and Akiyama S: Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res 55: 1687-1690, 1995.
14. Bronckaers A, Gago F, Balzarini J and Liekens S: The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev 29: 903-953, 2009.
15. Heggie GD, Sommadossi JP, Cross DS, Huster WJ and Diasio RB: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203-2206, 1987.
16. Champoux JJ: DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70: 369-413, 2001.
17. Topcu Z: DNA topoisomerases as targets for anticancer drugs. J Clin Pharm Ther 26: 405-416, 2001.
18. Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P, Klein P, Behan K, O'Connell MJ, Levitt R, Kugler JW, Tria Tirona M and Goldberg RM: Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 20: 1735-1743, 2002.
19. Boonsong A, Curran S, McKay JA, Cassidy J, Murray GI and McLeod HL: Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Hum Pathol 33: 1114-1119, 2002.
20. Bohmann K, Hennig G, Rogel U, Poremba C, Mueller BM, Fritz P, Stoerkel S and Schaefer KL: RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. Clin Chem 55: 1719-1727, 2009.
21. Hennig G, Gehrmann M, Stropp U, Brauch H, Fritz P, Eichelbaum M, Schwab M and Schroth W: Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. Clin Chem 56: 1845-1853, 2010.
22. Muller BM, Kronenwett R, Hennig G, Euting H, Weber K, Bohmann K, Weichert W, Altmann G, Roth C, Winzer KJ, Kristiansen G, Petry C, Dietel M and Denkert C: Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue - a new option for predictive biomarker assessment in breast cancer. Diagn Mol Pathol 20: 1-10, 2011.
23. Goeman JJ, van de Geer SA, de Kort F and van Houwelingen HC: A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 20: 93-99, 2004.
24. Tsujii M, Kawano S and DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340, 1997.
25. Ogino S, Kirkner GJ, Nosho K, Irahara N, Kure S, Shima K, Hazra A, Chan AT, Dehari R, Giovannucci EL and Fuchs CS: Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 14: 8221-8227, 2008.
26. Xia D, Wang D, Kim SH, Katoh H and DuBois RN: Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat Med 18: 224-226, 2012.
27. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188, 1994.
28. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA and Jothy S: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55: 2556-2559, 1995.
29. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, and Hla T: Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55: 3785-3789, 1995.
30. Roelofs HM, Te Morsche RH, van Heumen BW, Nagengast FM and Peters WH: Over-expression of COX-2 mRNA in colorectal cancer. BMC Gastroenterol 14: 1, 2014.
31. Chan AT, Ogino S, and Fuchs CS: Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302: 649-658, 2009.
32. Huh JW, Kim HR, Lee JH and Kim YJ: Comparison of cyclooxygenase-2 and CD44 mRNA expression in colorectal cancer and its relevance for prognosis. Virchows Arch 454: 381-387, 2009.
33. Uchida K, Schneider S, Yochim JM, Kuramochi H, Hayashi K, Takasaki K, Yang D, Danenberg KD and Danenberg PV: Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 11: 3363-3368, 2005.
34. Kim JG, Chae YS, Sohn SK, Moon JH, Ryoo HM, Bae SH, Kum Y, Jeon SW, Lim KH, Kang BM, Park IJ, Choi GS and Jun SH: Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. Cancer Chemother Pharmacol 64: 953-960, 2009.
35. Nishimura G, Terada I, Kobayashi T, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Kayahara M, Shimizu K, Ohta T and Miwa K: Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep 9: 479-482, 2002.
36. Lassmann S, Hennig M, Rosenberg R, Nahrig J, Schreglmann J, Krause F, Poignee-Heger M, Nekarda H, Hofler H and Werner M: Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up. Int J Colorectal Dis 21: 238-247, 2006.
37. Mimori K, Matsuyama A, Yoshinaga K, Yamashita K, Masuda T, Inoue H, Ueo H and Mori M: Localization of thymidine phosphorylase expression in colorectal carcinoma tissues by in situ RT-PCR assay. Oncology 62: 327-332, 2002.
38. Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, Yamada Y, Murata F and Aikou T: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88: 1110-1117, 1996.
39. Mori T, Ohue M, Takii Y, Hashizume T, Kato T, Kotake K, Sato T and Tango T: Factors predicting the response to oral fluoropyrimidine drugs: a phase II trial on the individualization of postoperative adjuvant chemotherapy using oral fluorinated pyrimidines in stage III colorectal cancer treated by curative resection (ACT-01 Study). Oncol Rep 29: 437-444, 2013.
40. Yasuno M, Mori T, Koike M, Takahashi K, Toi M, Takizawa T, Shimizu S, Yamaguchi T and Matsumoto H: Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma. Oncol Rep 13: 405-412, 2005.
41. Popat S, Matakidou A and Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22: 529-536, 2004.
42. Chen Y, Yi C, Liu L, Li B, Wang Y and Wang X: Thymidylate synthase expression and prognosis in colorectal cancer: a meta-analysis of colorectal cancer survival data. Int J Biol Markers 27: e203-211, 2012.
43. Lu Y, Zhuo C, Cui B, Liu Z, Zhou P, Lu Y and Wang B: TYMS serves as a prognostic indicator to predict the lymph node metastasis in Chinese patients with colorectal cancer. Clin Biochem 46: 1478-1483, 2013.
44. Klingbiel D, Missiaglia E, Yan P, Tejpar S, Roth A, d'Ario G, Delorenzi M and Bosman F: Thymidylate synthase (TS) expression as a prognostic molecular marker in stage II/III colon cancer. In: ASCO 2013. Chicago. J Clin Oncol (suppl 31): abstr 3577, 2013.
45. Karlberg M, Ohrling K, Edler D, Hallstrom M, Ullen H and Ragnhammar P: Prognostic and predictive value of thymidylate synthase expression in primary colorectal cancer. Anticancer Res 30: 645-651, 2010.
46. Etienne-Grimaldi MC, Bennouna J, Formento JL, Douillard JY, Francoual M, Hennebelle I, Chatelut E, Francois E, Faroux R, El Hannani C, Jacob JH and Milano G: Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. Br J Clin Pharmacol 73: 776-785, 2012.
47. Tan BR, Thomas F, Myerson RJ, Zehnbauer B, Trinkaus K, Malyapa RS, Mutch MG, Abbey EE, Alyasiry A, Fleshman JW and McLeod HL: Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. J Clin Oncol 29: 875-883, 2011.
48. Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G and Barone C: Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology 70: 366-377, 2006.
49. Amstutz U, Farese S, Aebi S and Largiader CR: Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics 10: 931-944, 2009.
50. Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, Guchelaar HJ, Smits PH, Beijnen JH, Punt CJ, Schellens JH and Cats A: Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 17: 3455-3468, 2011.
51. Paradiso A, Xu J, Mangia A, Chiriatti A, Simone G, Zito A, Montemurro S, Giuliani F, Maiello E and Colucci G: Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. Int J Cancer 111: 252-258, 2004.
52. Kostopoulos I, Karavasilis V, Karina M, Bobos M, Xiros N, Pentheroudakis G, Kafiri G, Papakostas P, Vrettou E and Fountzilas G: Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy. BMC Cancer 9: 339, 2009.
53. Romer MU, Nygard SB, Christensen IJ, Nielsen SL, Nielsen KV, Muller S, Smith DH, Vainer B, Nielsen HJ and Brunner N: Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis. Mol Oncol 7: 101-111, 2013.
54. Griffin MR, Bergstralh EJ, Coffey RJ, Beart RW Jr. and Melton LJ, 3rd: Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer 60: 2318-2324, 1987.
55. Muss H and Bynum D: Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An Underused Lifesaving Treatment. J Clin Oncol 30: 2576-2578, 2012.